openPR Logo
Press release

Graft Versus Host Disease Market: Growth & Forecasts, 2033

Graft Versus Host Disease Market

Graft Versus Host Disease Market

The new report published by The Business Research Company, titled Graft Versus Host Disease (GVHD) Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the graft versus gost disease (GVHD) market size has grown strongly in recent years. It will grow from $2.65 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The graft versus gost disease (GVHD) market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15579&type=smp

Hematological Disorders Fueling Growth In Graft Versus Host Disease (GVHD) Treatment Market
The rising hematological disorders are expected to propel the growth of the graft versus host disease (GVHD) treatment market going forward. Hematological disorders, also known as blood disorders, encompass a wide range of conditions affecting the blood and its components, including red blood cells, white blood cells, platelets, and plasma. Hematological disorders is creating a wide space due to unhealthy lifestyle habits, genetic predisposition, and exposure to certain environmental toxins, such as radiation, chemicals, and pollutants. GVHD treatment strategies developed for managing GvHD can have broader implications for patients with hematological disorders, offering new avenues for immune modulation and improved disease management. For instance, in 2023, according to the Leukemia & Lymphoma Society, a US-based healthcare organization, Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 57,380 people in the US in 2023. This represents approximately 157 people each day or more than six people every hour die in the US from blood cancer. Therefore, the rising hematological disorders drive the graft versus host disease (GVHD) treatment market.

Driving Innovation in GVHD Treatment Market through Advanced Drug Development
Major companies operating in the graft versus host disease (GVHD) treatment market are developing advanced drugs and seeking their approval for the treatment of graft versus host disease (GVHD) treatment that gain a competetive edge in the market. Product approvals are critical for ensuring that healthcare products meet the necessary standards for safety, efficacy, and quality before they are made available to patients. For instance, in March 2023, Incyte corporation, a US-based healthcare company developed a ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, approved by the Food and Drug Administration, a US-based healthcare organization. These tablets were intended for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).

The graft versus host disease (GVHD) treatment market covered in this report is segmented -

1) By Product Type: Corticosteroids, Monoclonal Antibodies, Immunosuppressants, Others
2) By Disease Type: Acute GvHD, Prophylaxis GvHD, Chronic GvHD
3) By End User: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15579&type=discount

Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix

Contents of the report:
1. Executive Summary
2. Graft Versus Host Disease (GVHD) Treatment Market Report Structure
3. Graft Versus Host Disease (GVHD) Treatment Market Trends And Strategies
4. Graft Versus Host Disease (GVHD) Treatment Market - Macro Economic Scenario
5. Graft Versus Host Disease (GVHD) Treatment Market Size And Growth
…..
27. Graft Versus Host Disease (GVHD) Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/graft-versus-host-disease-gvhd-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Graft Versus Host Disease Market: Growth & Forecasts, 2033 here

News-ID: 3562850 • Views:

More Releases from The Business research company

Evolving Market Trends In The Integrated Geophysical Services Industry: Enhancing Geophysical Surveys With Drones For Efficiency In Harsh Environments
Evolving Market Trends In The Integrated Geophysical Services Industry: Enhancin …
The Integrated Geophysical Services Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Integrated Geophysical Services Market Size During the Forecast Period? The integrated geophysical services market has experienced consistent growth in recent years, expected to rise from $2.35 billion in 2024 to
Global HR Advisory Services Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
Global HR Advisory Services Market: Key Trends, Market Share, Growth Drivers, An …
The HR advisory services market report describes and explains the HR advisory services market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global HR advisory services market reached a value of nearly $155.74 billion in 2024, having grown at a compound annual growth rate (CAGR) of 4.22% since
High Voltage Aluminium Electrolytic Capacitors Global Market Report 2025: Size, Trends, and Growth Insights for Global Expansion
High Voltage Aluminium Electrolytic Capacitors Global Market Report 2025: Size, …
The high voltage aluminum electrolytic capacitors report describes and explains the high voltage aluminum electrolytic capacitors market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global high voltage aluminum electrolytic capacitors market reached a value of nearly $4.10301 billion in 2024, having grown at a compound annual growth
Global Vertical Market Software Market: Key Trends, Market Share, Growth Drivers, and Forecast for 2025-2034
Global Vertical Market Software Market: Key Trends, Market Share, Growth Drivers …
The vertical market software report describes and explains the vertical market software market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global vertical market software market reached a value of nearly $152.61027 billion in 2024, having grown at a compound annual growth rate (CAGR) of 12.11% since 2019.

All 5 Releases


More Releases for GVHD

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape. Graft-versus-host disease (GVHD) is a complication that can occur after
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a